Get the Stockscreener App
1.09
1.01%
0.01
An 2 Therapeutics Inc stock is traded at $1.09, with a volume of 66,346.
It is up +1.01% in the last 24 hours and up +1.95% over the past month.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
See More
Previous Close:
$1.08
Open:
$1.09
24h Volume:
66,346
Relative Volume:
0.11
Market Cap:
$32.23M
Revenue:
-
Net Income/Loss:
$-64.73M
P/E Ratio:
-0.3893
EPS:
-2.8
Net Cash Flow:
$-53.29M
1W Performance:
-1.72%
1M Performance:
+1.95%
6M Performance:
-57.39%
1Y Performance:
-92.76%
1-Day Range:
$1.08
$1.10
1-Week Range:
$1.07
$1.12
52-Week Range:
$0.87
$22.22
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Name
An 2 Therapeutics Inc
Sector
Industry
Phone
(650) 331-9090
Address
1800 EL CAMINO REAL, SUITE D, MENLO PARK
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
An 2 Therapeutics Inc Stock (ANTX) Latest News
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) - BioSpace
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study - Yahoo Finance
Intellia Presents Positive Results from the Phase 2 Study - GlobeNewswire
Viking Therapeutics Inc (VKTX) Q3 2024 Earnings Call Highlights: Strong Financial Position Amid ... - Yahoo Finance
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 - GlobeNewswire
Summit Therapeutics Inc (SMMT) Q2 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease - Business Wire
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. - GlobeNewswire
Around the Helix: Cell and Gene Therapy Company Updates – October 2, 2024 - CGTLive™
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 - Yahoo Finance
Araris Doubles Down With Dual-payload ADC - BioProcess Online
Black Diamond Therapeutics Announces Initial Phase 2 Data - GlobeNewswire
Ildikó Enyedi working on her new feature, Silent Friend - Cineuropa
Boss Brown calls on Ayr players to step up after losing top scorer for season - Ayr Advertiser
Black Diamond Therapeutics to Host Webcast Presentation of - GlobeNewswire
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC - Yahoo Finance
Scott Brown admits Anton Dowds injury is huge blow for Ayr United as he challenges others to step up - Daily Record
Adicet Bio shares hold neutral rating amid positive study data By Investing.com - Investing.com South Africa
Adicet Bio reports promising ADI-001 therapy data - Investing.com
Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug - XM
Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting - BioSpace
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) - Business Wire
Agatha All Along Episode 2 Cast & Characters Guide (Photos) - The Direct
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 - GlobeNewswire
iView Therapeutics completes enrollment in phase 1/2 trial for ophthalmic eyelid wipe for the treatment of dry eye disease - Ophthalmology Times
VERV CLASS ACTION: Verve Therapeutics, Inc. Stockholders - GlobeNewswire
IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients - PR Newswire
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern - Yahoo Finance
Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024 - Yahoo Finance
Acrivon Therapeutics Reports Positive Endometrial Cancer - GlobeNewswire
Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration - PR Newswire
Intellia Therapeutics to Present Data from the Phase 2 - GlobeNewswire
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting - Yahoo Finance
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2) - GlobeNewswire
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024 - Newsfile
Protara Therapeutics Announces Completion of First Cohort - GlobeNewswire
Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial - GlobeNewswire
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts - Yahoo Finance
Dyne Therapeutics Announces New Clinical Data from Phase - GlobeNewswire
Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients (SLNO) - Seeking Alpha
Innovo Therapeutics Inc. Announces Phase 2 Clinical Results Demonstrating the Innovative Efficacy of INV-001 for the Treatment of Post-thyroidectomy Scars - Winchester Herald Chronicle
Director J Singleton Sells 5,700 Shares of Viking Therapeutics Inc (VKTX) - Yahoo Finance
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease - Yahoo Finance
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - Yahoo Finance
iTeos Therapeutics Announces Late-Breaking Oral - GlobeNewswire
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024 - Yahoo Finance
Scorpion Therapeutics to Present STX-478 Initial Phase 1/2 Data at ESMO Congress 2024 - Business Wire
Why Is Viking Therapeutics, Inc. (VKTX) the Best Diabetes Stock to Buy Now? - Yahoo Finance
Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year? - Yahoo Finance
An 2 Therapeutics Inc Stock (ANTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):